Category: Epidiolex

analysis, analytics, business, cannabis, cbd, compliance, consumer, cultivation, Epidiolex, europe, European, extraction, Federal, government, growing, industry, international, lab, laboratories, laboratory, labs, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, product, Quality, regulation, regulations, regulatory, retail, safety, state, test, Testing, UK, union, United Kingdom, United States

The CBD Regulatory Environment in Europe: Part 4

The CBD Regulatory Environment in Europe: Part 4

This is the final piece of a four-part series discussing European cannabis regulations. Click here for Part One, here for Part Two and here […]

analysis, business, cannabis, cbd, compliance, consumer, cultivation, Epidiolex, EU, European, extraction, farm bill, FDA, Federal, FSA, government, growing, GW Pharma, industry, international, laboratories, laboratory, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, product, Quality, regulation, regulations, regulatory, retail, safety, state, test, Testing, thc, UK, union, United Kingdom

The CBD Regulatory Environment in Europe: Part 3

The CBD Regulatory Environment in Europe: Part 3

This is Part Three of a four-part series discussing European cannabis regulations. Click here for Part One and here for Part Two. Part […]

american, analysis, analytics, authority, British, business, cannabis, cbd, compliance, consumer, cultivation, dispensary, EFSA, Epidiolex, europe, European, export, extraction, FDA, Federal, food, government, growing, import, industry, international, lab, laboratories, laboratory, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, product, Quality, regulation, regulations, regulatory, safety, state, thc, UK, union, United Kingdom, United States

The CBD Regulatory Environment in Europe: Part 2

The CBD Regulatory Environment in Europe: Part 2

This is Part Two of a four-part series discussing European cannabis regulations. Click here for Part One. Part Two analyzes the differences […]

ABCann, administration, analysis, analytics, Aphria, Aurora, business, Business Analysis, cannabis, Canopy, cbd, condition, dispensary, Epidiolex, Federal, global, government, growing, GW Pharma, industry, insights, latin america, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicinal, medicine, pharmaceutical, Quality, recreational, regulation, regulations, regulatory, safety, state, supreme, thc, topical, world, worldwide

5 Pivotal Trends Propelling Growth For the Medical Cannabis Market: 2021-2027

5 Pivotal Trends Propelling Growth For the Medical Cannabis Market: 2021-2027

Growing awareness and public support for medical cannabis around the world has pushed regulatory authorities to consider the legalization of medical cannabis, […]

Canadian Medical Marijuana & Cannabis Industry News, Cannabis Industry & Marijuana Business Briefs, cannabis lawsuit, Canopy Growth, cbd, CO2 extraction, Epidiolex, Europe Cannabis Industry & Marijuana Business News, GW Pharma, GW Pharmaceuticals, intellectual property, International Marijuana Business News, marijuana intellectual property, Marijuana Legalization and Regulatory News for Cannabis Businesses, Medical Cannabis Industry & Recreational Marijuana Business News, U.S. District Court, United States Cannabis Industry & Marijuana Business News

Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement

Canadian cannabis producer Canopy Growth Corp. is suing Britain’s GW Pharmaceuticals in U.S. federal court, alleging that GW is knowingly infringing upon […]

1, analysis, analytics, and Cosmetics Act, application, approval, approve, business, Business Analysis, cannabidiol, cannabis, cbd, clinical, clinical trials, compliance, consumer packaged goods, CPG, CSA, dea, derived, deschedule, descheduled, Dravet syndrome, drug, Drug Enforcement Administration, Epidiolex, epilepsy, extraction, FDA, FDCA, Federal, Federal Food, FFDCA, food and drug administration, formulation, government, GW, GW Pharma, hemp, industry, law, legal, legalization, legalize, legislation, Lennox-Gastaut syndrome, license, marijuana, market, medical, medicine, New, patent, pathway, patient, pharma, pharmaceutical, product, Product Development, program, regulation, regulations, regulatory, REMS, safety, schedule, seizures, state, Substances, thc, trial, TSC

How GW Pharma Won CBD

How GW Pharma Won CBD

As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]

Asia & Oceania Cannabis Industry & Marijuana Business News, Australia, Cannabis Industry & Marijuana Business Briefs, Epidiolex, Epidyolex, GW Pharmaceuticals, International Marijuana Business News, Medical Cannabis Industry & Recreational Marijuana Business News

GW Pharmaceuticals cannabis drug gets regulatory OK in Australia

GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in treating seizures related to […]

Cannabis Industry & Marijuana Business Briefs, Coronavirus, Epidiolex, Europe Cannabis Industry & Marijuana Business News, GW Pharmaceuticals, International Marijuana Business News, Marijuana Stocks & Publicly Traded Cannabis Companies, United Kingdom, United States Cannabis Industry & Marijuana Business News

Epidiolex maker GW Pharma turns in flat second quarter on pandemic impact

United Kingdom-based GW Pharmaceuticals posted marginal revenue growth in the second quarter over the previous quarter, citing challenges stemming from the COVID-19 […]